Have a feature idea you'd love to see implemented?
Let us know!
SAGE Sage Therapeutics Inc
Price (delayed)
$5.61
Market cap
$343.18M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.57
Enterprise value
$252.5M
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing
Highlights
The net income has increased by 49% year-on-year and by 24% since the previous quarter
Sage Therapeutics's EPS has increased by 49% YoY and by 25% from the previous quarter
SAGE's gross margin is up by 6% YoY but it is down by 3.9% QoQ
The company's debt rose by 47% YoY
SAGE's equity is down by 32% YoY and by 12% from the previous quarter
Key stats
What are the main financial stats of SAGE
Market
Valuations
Earnings
Shares outstanding
61.17M
Market cap
$343.18M
Enterprise value
$252.5M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.62
Price to sales (P/S)
3.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.37
Revenue
$106.4M
Gross profit
$97.63M
Net income
-$337.59M
EBIT
-$337.59M
EBITDA
-$336.28M
Free cash flow
-$320.04M
Per share
Balance sheet
Liquidity
EPS
-$5.57
EPS diluted
-$5.57
Free cash flow per share
-$5.24
Book value per share
$9.04
Revenue per share
$1.74
TBVPS
$10.18
Total assets
$622.43M
Total liabilities
$70.6M
Debt
$10.27M
Equity
$551.84M
Working capital
$544.58M
Debt to equity
0.02
Current ratio
10.02
Quick ratio
9.69
Net debt/EBITDA
0.27
Margins
Efficiency
Dividend
EBITDA margin
-316.1%
Gross margin
91.8%
Net margin
-317.3%
Operating margin
-349.9%
Return on assets
-45.5%
Return on equity
-50.3%
Return on invested capital
-59.6%
Return on capital employed
-60.1%
Return on sales
-317.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SAGE stock price
How has the Sage Therapeutics stock price performed over time
Intraday
12.2%
1 week
4.18%
1 month
14.26%
1 year
-73.13%
YTD
-74.11%
QTD
-22.3%
Financial performance
How have Sage Therapeutics's revenue and profit performed over time
Revenue
$106.4M
Gross profit
$97.63M
Operating income
-$372.25M
Net income
-$337.59M
Gross margin
91.8%
Net margin
-317.3%
The company's net margin has surged by 95% YoY and by 31% QoQ
Sage Therapeutics's operating margin has surged by 94% YoY and by 30% QoQ
The net income has increased by 49% year-on-year and by 24% since the previous quarter
Sage Therapeutics's operating income has increased by 46% YoY and by 23% from the previous quarter
Growth
What is Sage Therapeutics's growth rate over time
Valuation
What is Sage Therapeutics stock price valuation
P/E
N/A
P/B
0.62
P/S
3.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.37
Sage Therapeutics's EPS has increased by 49% YoY and by 25% from the previous quarter
The P/B is 69% less than the 5-year quarterly average of 2.0 and 52% less than the last 4 quarters average of 1.3
SAGE's equity is down by 32% YoY and by 12% from the previous quarter
SAGE's P/S is 98% below its 5-year quarterly average of 188.6 and 66% below its last 4 quarters average of 9.6
The revenue has increased by 9% from the previous quarter
Efficiency
How efficient is Sage Therapeutics business performance
Sage Therapeutics's ROS has soared by 95% YoY and by 31% from the previous quarter
Sage Therapeutics's ROE has increased by 20% YoY and by 17% from the previous quarter
SAGE's ROA is up by 20% year-on-year and by 16% since the previous quarter
The ROIC has grown by 18% YoY and by 17% from the previous quarter
Dividends
What is SAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SAGE.
Financial health
How did Sage Therapeutics financials performed over time
Sage Therapeutics's total liabilities has decreased by 47% YoY but it has increased by 2.3% QoQ
SAGE's quick ratio is up by 43% YoY
The company's debt is 98% lower than its equity
The debt to equity has soared by 100% YoY
The company's debt rose by 47% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.